Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03526588 · ClinicalTrials.gov registry record · Phase 1
Umbilical Cord Blood Mononuclear Cells for Hypoxic Neurologic Injury in Infants With Congenital Diaphragmatic Hernia (CDH)
A Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03526588: Clinical Trial Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
NCT03526588 is a Phase 1 study that was terminated before completion, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03526588, a Phase 1 study, was terminated before completion, sponsored by The University of Texas Health Science Center, Houston.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the use of autologous umbilical cord blood (UCB) mononuclear cells to mitigate hypoxic neurologic injury among infants with high-risk congenital diaphragmatic hernia (CDH).
Interventions
- BIOLOGICAL Autologous umbilical cord blood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2024-07-01 |
| Phase | Phase 1 |
Why NCT03526588 stopped before completion
NCT03526588 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Autologous umbilical cord blood is the first listed.
NCT03526588 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03526588 about?
NCT03526588 is a clinical study titled "Umbilical Cord Blood Mononuclear Cells for Hypoxic Neurologic Injury in Infants With Congenital Diaphragmatic Hernia (CDH)". The purpose of this study is to investigate the use of autologous umbilical cord blood (UCB) mononuclear cells to mitigate hypoxic neurologic injury among infants with high-risk congenital diaphragmatic hernia (CDH).
What is the current status of trial NCT03526588?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2018-08-01. Estimated completion is 2024-07-01.
What interventions are being tested in trial NCT03526588?
The interventions under investigation include: Autologous umbilical cord blood (BIOLOGICAL).
Who is sponsoring clinical trial NCT03526588?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03526588's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI